Immune checkpoint inhibitors‑associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group
-
Manuel Sánchez Cánovas [3] ; Miguel Ángel Moya Hernández [4] ; Evdochia Adoamnei [1] ; Diego Cacho Lavin [3] ; David Fernández Garay [3] ; Teresa Quintanar Verdúguez [3] ; Jacobo Rogado Revuelta [2] ; Francisco José García Verdejo [5] ; Silvia García Adrián [3] ; Ana Isabel Ferrer Pérez [3] ; María Esperanza Guirao García [3] ; Javier López Robles [3] ; Jaime Mendiola [1] ; Andrés J. Muñoz Martín [3]
-
[1] Universidad de Murcia
Universidad de Murcia
Murcia, España
-
[2] Hospital Infanta Leonor
Hospital Infanta Leonor
Madrid, España
-
[3] Spanish Society of Medical Oncology (SEOM) Thrombosis and Cancer Group, Madrid, Spain
-
[4] Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
-
[5] Medical Oncology Department, Complejo Hospitalario de Jaén, Jaén, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 1, 2025, págs. 175-181
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose Both venous and arterial thrombotic events (VTE/AT) can be associated with Immune Checkpoint Inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice.
Methods /Patients. This retrospective, multicenter study was promoted by the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM). Individuals with head and neck cancer who initiated ICI between 01/01/2015 and 31/12/2021 were recruited. Minimum follow-up was 6 months (except in cases of demise). The primary objective was to calculate the incidence of ICI-associated VTE/AT, with secondary objectives including the analysis of their impact on survival and the identification of variables predictive of VTE/AT.
Results A total of 143 patients with head and neck cancer were enrolled. The incidence of VTE/AT during follow-up (median 8.6 months) was 2.8%. Survival analysis showed no significant differences (p = 0.644) between the group that developed VTE/AT (median 7.13 months, 95% CI 0–22.9) and the group that did not (median 9.86 months, 95% CI 6.3–13.4). The presence of liver metastases was predictive of VTE/AT (p < 0.05).
Conclusions Thromboembolic disease associated with immunotherapy in patients with head and neck neoplasia does not significantly impact survival. The presence of liver metastases can predict these events.
